

FFU

Docket No. 5063 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	) Group Art Unit: 1632
Luz MONTESCLAROS et al.	) Examiner: To be assigned
Serial No.: 10/618,493	CERTIFICATE OF MAILING under 37 C.F.R. 1.8
Filed: July 11, 2003	I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:
For: METHODS AND KITS FOR OBTAINING NUCLEIC ACID	September 14, 2005 Date of Deposit
FROM BIOLOGICAL SAMPLES	Deborah A. Mojarro
Confirmation No.: 5407	Signature of Degos ting Party
	)

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO/SB/08A) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) [] accompanies a new patent application submitted herewith.
- (b) [] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) [] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.
- (d)[X] as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.

- (e) [] is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.
- (f) [] is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the information disclosure statement. The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

- [] Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

A copy of the items on PTO/SB/08A are supplied herewith.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that

any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: 0 13 05

Scott R. Bortner, Reg. No. 34,298

Attorney for Applicants

## Correspondence Address

Customer Number 22896 APPLERA CORPORATION Applied Biosystems Group 850 Lincoln Centre Drive Foster City, CA 94404 (650) 638-6245 (Phone) (650) 638-6677 (Fax)

Please type a plus sign (+) inside this box.
--

Sheet

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nd to a collection of information unless it displays a valid OMB control number. 2005

Substitute for form 1449A/PTO	7	ပြီး Co
Substitute for form 1449AF 10		Application Number
INFORMATION DISC	TI OSTABLE	Filing Date
		First Named Inventor
STATEMENT BY APP	LICANI	Group Art Unit

2

(Use as many sheets as necessary)

1

of

Complete if Known			
Application Number 10/618,493			
Filing Date	July 11, 2003		
First Named Inventor	Luz MONTESCLAROS et al.		
Group Art Unit	1632		
Examiner Name	To Be Assigned		
Attorney Docket No.	5063 119		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent D Number	Nocument Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	01	5,234,809		Boom et al.	08-10-1993	
	<u> </u>					

	FOREIGN PATENT DOCUMENTS							
Examiner			Foreign Patent Document		Name of Patentee or	Date of Publication	Pages, Columns, Lines	
Initials*	No. 1	Office <sup>3</sup>	Number⁴	Kind Code <sup>5</sup> (if known)	Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
<u> </u>								
	-	+ +						_
	<u> </u>		·					
İ							1	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PT	D/SB/0	A80	(08-00)
)/31/2002.	OMB	065	1-0031

u.S. Patent and Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Please type a plus sign (+) inside this box.  $\longrightarrow$  +

	PTO/SB/08A (08-00)
Approved for use	e through 10/31/2002. OMB 0651-0031
nd Trademark Office:	U.S. DEPARTMENT OF COMMERCE
of information unlace	it displays a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

SEP 1 6 2005

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) 2 of

Complete if Known			
Application Number 10/618,493			
Filing Date	July 11, 2003		
First Named Inventor   Luz MONTESCLAROS et al			
Group Art Unit	1632		
Examiner Name	To Be Assigned		
Attorney Docket No.	5063 US		

	OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	02	APPLIED BIOSYSTEMS, "DNA Isolation From Fresh And Frozen Blood, Tissue Culture Cells, and Buccal Swabs", Protocol Product Manual, Copyright 2003, pp. 1-56		
	03	APPLIED BIOSYSTEMS, "Isolation of Total RNA From Cultured Cells-ABI Prism <sup>tm</sup> 6700 Automated Nucleic Acid Workstation or 6100 Nucleic Acid PrepStation", Protocol Product Manual, Copyright 2002, pp. 1-46		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.